← Emergent BioSolutions Inc. (EBS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Emergent BioSolutions Inc. (EBS)
Pharmaceutical Preparations · market cap $341M · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Emergent BioSolutions (EBS) is a Gaithersburg-based specialty biopharmaceutical company with ~1,600 employees focused on biodefense vaccines, antibody therapeutics, and opioid-overdose countermeasures. Revenue has declined sharply from $1.79B in 2021 to $743M in 2025, reflecting the wind-down of COVID-related manufacturing contracts. The company carries $429M in net debt against $160M in cash (~14 months runway), with a market cap of ~$422M.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dose of 5.0 x 10^9 CFU (Cohort 1) | Phase 2 | Typhoid |
| FLU-IGIV | Phase 2 | Influenza A H3N2 |
| AV7909 | Phase 3 | Anthrax |
| ACAM2000 | Phase 3 | Smallpox Vaccine Adverse Reaction |
| BioThrax | Phase 3 | Anthrax |
| Vaccinia virus: ACAM2000 smallpox vaccine | Phase 2 | Smallpox |
| ACAM2000 Smallpox Vaccine | Phase 2 | Smallpox |
| AIGIV 3.5 mg/kg | Phase 2 | Anthrax |
| HuMax-CD4 | Phase 3 | T Cell Lymphoma |
Price & technical context
3-month
-23.1%
6-month
-24.0%
12-month
-27.8%
52-wk range
$4.45–$13.90
vs 50-day MA
+3.5%
vs 200-day MA
-26.2%
Realized vol
80.4%
Max drawdown
-68.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EBS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.